{"id":46115,"date":"2022-07-13T13:01:52","date_gmt":"2022-07-13T11:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/"},"modified":"2022-07-13T13:01:52","modified_gmt":"2022-07-13T11:01:52","slug":"glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/","title":{"rendered":"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Conference Call and Webcast Scheduled for 1:30 p.m. PT<\/i>\n<\/p>\n<p>ALISO VIEJO, Calif.&#8211;(BUSINESS WIRE)&#8211;Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The company\u2019s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 3, 2022.\n<\/p>\n<p>\nA link to the live webcast will be available on the company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.glaukos.com&amp;esheet=52779005&amp;newsitemid=20220713005101&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.glaukos.com&amp;index=1&amp;md5=bfdc4564bb88bd62a1a3a788ae069126\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/investors.glaukos.com<\/a>. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company\u2019s website following completion of the call.\n<\/p>\n<p>\n<b>About Glaukos<\/b>\n<\/p>\n<p>\nGlaukos (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glaukos.com&amp;esheet=52779005&amp;newsitemid=20220713005101&amp;lan=en-US&amp;anchor=www.glaukos.com&amp;index=2&amp;md5=ae9909626d8875d550312e645108e54e\" rel=\"nofollow noopener\" shape=\"rect\">www.glaukos.com<\/a>) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and has since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nChris Lewis<br \/>\n<br \/>Vice President, Investor Relations and Corporate Affairs<br \/>\n<br \/>(949) 481-0510<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;c&#x6c;&#x65;&#119;is&#x40;&#103;&#108;a&#x75;&#x6b;&#111;s&#x2e;&#x63;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#108;&#x65;&#x77;i&#x73;&#64;g&#x6c;&#97;u&#x6b;&#111;&#x73;&#x2e;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.&#8211;(BUSINESS WIRE)&#8211;Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46115","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.&#8211;(BUSINESS WIRE)&#8211;Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-13T11:01:52+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3\",\"datePublished\":\"2022-07-13T11:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/\"},\"wordCount\":263,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/\",\"name\":\"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-07-13T11:01:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/","og_locale":"en_US","og_type":"article","og_title":"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 - Pharma Trend","og_description":"Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif.&#8211;(BUSINESS WIRE)&#8211;Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-13T11:01:52+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3","datePublished":"2022-07-13T11:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/"},"wordCount":263,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/","url":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/","name":"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-07-13T11:01:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/glaukos-to-release-second-quarter-2022-financial-results-after-market-close-on-august-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46115"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46115\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}